newsfilter
← Latest News
GlobeNewswire·

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that